Evidence map›Paper›PMID 40579659›Full record

ArticleWorld journal of pediatrics : WJP2025

Systemic corticosteroid use and neurodevelopmental outcomes in preterm infants: a cohort study.

Adithya Shastry, Danish Ahmad, Alice Richardson, Barbara Bajuk, Traci-Anne Goyen, Pranav R Jani, Mohamed E Abdel-Latif, Neonatal Intensive and Special Care Units’ Data Registry (NICUS)

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of pediatrics : WJP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adithya ShastryDepartment of Neonatology, The Australian National University Medical School, Centenary Hospital for Women and Children, Canberra Hospital, PO Box 11, Garran, Canberra, ACT, Woden ACT 2606, Australia.
Danish AhmadSchool of Medicine and Psychology, College of Science and Medicine, Australian National University, Acton, Canberra, ACT, Australia.
Alice RichardsonStatistical Support Network, Australian National University, Acton, Canberra, ACT, Australia.
Barbara BajukNSW Pregnancy and Newborn Services Network, Sydney Children's Hospitals Network, Randwick, NSW, Australia.
Traci-Anne GoyenDepartment of Neonatology, Westmead Hospital, Westmead, NSW, Australia.
Pranav R JaniDepartment of Neonatology, Westmead Hospital, Westmead, NSW, Australia.
Mohamed E Abdel-LatifDepartment of Neonatology, The Australian National University Medical School, Centenary Hospital for Women and Children, Canberra Hospital, PO Box 11, Garran, Canberra, ACT, Woden ACT 2606, Australia. Abdel-Latif.Mohamed@act.gov.au.ORCID 0000-0003-4306-2933
Neonatal Intensive and Special Care Units’ Data Registry (NICUS)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe risk-benefit balance and safety of postnatal corticosteroid use for chronic lung disease (PNCSCLD) in preterm infants is a controversial matter. Our objective was to determine the trends in the use of PNCSCLD over eleven years and to analyze the neurodevelopmental consequences of PNCSCLD in preterm infants at 18-42 months of corrected age.

methodsThe data for this retrospective population-based cohort study were obtained from ten tertiary neonatal intensive care units across New South Wales and the Australian Capital Territory, Australia. Preterm infants < 29

resultsOver eleven years, 611 (14.3%) out of 4258 infants received PNCSCLD. Among the 3386 eligible infants, 2636 (77.8%) underwent neurodevelopmental follow-up and were included in the final analysis. The rate of PNCSCLD use increased from 12.4% in 2007 to 19.6% in 2017. Similarly, the rate of moderate to severe functional disability (MSFD) increased from 8.8% in 2007 to 16.1% in 2017. Propensity-adjusted analysis revealed a greater odds ratio (OR) for MSFD in the PNCSCLD group than in the control group [average treatment effect: OR = 1.252, 95% confidence interval (CI) = 1.185-1.322, P ≤ 0.001; average treatment effect on the treated group: OR = 1.104, 95% CI = 1.031-1.184, P = 0.005].

conclusionsPNCSCLD use was associated with a greater incidence of MSFD. Clinicians should exercise caution when using PNCSCLD.

Indexed as

Adrenal Cortex HormonesInfant, Premature, DiseasesLung DiseasesNeurodevelopmental DisordersChild, PreschoolChronic DiseaseCohort StudiesFemaleHumansInfantInfant, NewbornInfant, PrematureIntensive Care Units, NeonatalMaleNew South WalesRetrospective StudiesAdrenal Cortex HormonesNeurosensoryOutcomePretermSteroid

Identifiers

PMID40579659
PMCPMC12245963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.